Supporting new vaccine introduction decisions: Lessons learned from the Hib Initiative experience

R. A. Hajjeh; L. Privor-Dumm; K. Edmond; R. O'Loughlin; S. Shetty; U. K. Griffiths; A. P. Bear; A. L. Cohen; A. Chandran; A. Schuchat; E. K. Mulholland; M. Santosham

doi:10.1016/j.vaccine.2010.07.028

Supporting new vaccine introduction decisions: Lessons learned from the Hib Initiative experience

R. A. Hajjeh, L. Privor-Dumm, K. Edmond, R. O'Loughlin, S. Shetty, U. K. Griffiths, A. P. Bear, A. L. Cohen, A. Chandran, A. Schuchat, E. K. Mulholland, M. Santosham

Bloomberg School of Public Health

Research output: Contribution to journal › Article › peer-review

42 Scopus citations

Abstract

The introduction of Haemophilus influenzae type b (Hib) vaccine in developing countries has suffered from a long delay. Between 2005 and 2009, a surge in Hib vaccine adoption took place, particularly among GAVI-eligible countries. Several factors contributed to the increase in Hib vaccine adoption, including support provided by the Hib Initiative, a project funded by the GAVI Alliance in 2005 to accelerate evidence-informed decisions for use of Hib vaccine. This paper reviews the strategy adopted by the Hib Initiative and the lessons learned in the process, which provide a useful model to accelerate uptake of other new vaccines.

Original language	English (US)
Pages (from-to)	7123-7129
Number of pages	7
Journal	Vaccine
Volume	28
Issue number	43
DOIs	https://doi.org/10.1016/j.vaccine.2010.07.028
State	Published - Oct 8 2010

Keywords

Developing countries
Haemophilus influenzae type b (Hib)
Vaccine

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2010.07.028

Cite this

@article{e8cadf7bec3d4d439f694ebf3235c568,

title = "Supporting new vaccine introduction decisions: Lessons learned from the Hib Initiative experience",

abstract = "The introduction of Haemophilus influenzae type b (Hib) vaccine in developing countries has suffered from a long delay. Between 2005 and 2009, a surge in Hib vaccine adoption took place, particularly among GAVI-eligible countries. Several factors contributed to the increase in Hib vaccine adoption, including support provided by the Hib Initiative, a project funded by the GAVI Alliance in 2005 to accelerate evidence-informed decisions for use of Hib vaccine. This paper reviews the strategy adopted by the Hib Initiative and the lessons learned in the process, which provide a useful model to accelerate uptake of other new vaccines.",

keywords = "Developing countries, Haemophilus influenzae type b (Hib), Vaccine",

author = "Hajjeh, {R. A.} and L. Privor-Dumm and K. Edmond and R. O'Loughlin and S. Shetty and Griffiths, {U. K.} and Bear, {A. P.} and Cohen, {A. L.} and A. Chandran and A. Schuchat and Mulholland, {E. K.} and M. Santosham",

year = "2010",

month = oct,

day = "8",

doi = "10.1016/j.vaccine.2010.07.028",

language = "English (US)",

volume = "28",

pages = "7123--7129",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "43",

}

TY - JOUR

T1 - Supporting new vaccine introduction decisions

T2 - Lessons learned from the Hib Initiative experience

AU - Hajjeh, R. A.

AU - Privor-Dumm, L.

AU - Edmond, K.

AU - O'Loughlin, R.

AU - Shetty, S.

AU - Griffiths, U. K.

AU - Bear, A. P.

AU - Cohen, A. L.

AU - Chandran, A.

AU - Schuchat, A.

AU - Mulholland, E. K.

AU - Santosham, M.

PY - 2010/10/8

Y1 - 2010/10/8

N2 - The introduction of Haemophilus influenzae type b (Hib) vaccine in developing countries has suffered from a long delay. Between 2005 and 2009, a surge in Hib vaccine adoption took place, particularly among GAVI-eligible countries. Several factors contributed to the increase in Hib vaccine adoption, including support provided by the Hib Initiative, a project funded by the GAVI Alliance in 2005 to accelerate evidence-informed decisions for use of Hib vaccine. This paper reviews the strategy adopted by the Hib Initiative and the lessons learned in the process, which provide a useful model to accelerate uptake of other new vaccines.

AB - The introduction of Haemophilus influenzae type b (Hib) vaccine in developing countries has suffered from a long delay. Between 2005 and 2009, a surge in Hib vaccine adoption took place, particularly among GAVI-eligible countries. Several factors contributed to the increase in Hib vaccine adoption, including support provided by the Hib Initiative, a project funded by the GAVI Alliance in 2005 to accelerate evidence-informed decisions for use of Hib vaccine. This paper reviews the strategy adopted by the Hib Initiative and the lessons learned in the process, which provide a useful model to accelerate uptake of other new vaccines.

KW - Developing countries

KW - Haemophilus influenzae type b (Hib)

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=77957366311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957366311&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.07.028

DO - 10.1016/j.vaccine.2010.07.028

M3 - Article

C2 - 20659515

AN - SCOPUS:77957366311

SN - 0264-410X

VL - 28

SP - 7123

EP - 7129

JO - Vaccine

JF - Vaccine

IS - 43

ER -

Supporting new vaccine introduction decisions: Lessons learned from the Hib Initiative experience

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this